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04 The Journal of Thoracic and Cardiobjective: This study was undertaken to review the initial results and surgical safety
ata for the US Food and Drug Administration safety and feasibility trial of the
aracor HeartNet (Paracor Medical, Inc, Sunnyvale, Calif.) myocardial constraint
evice.
ethods: Patients with New York Heart Association functional class II or III heart
ailure underwent device implantation (n  21) through a left minithoracotomy.
esults: The average age was 53 years (31–72 years). There were 18 men and 3
omen, and 17 patients had nonischemic etiology of heart failure. Mean heart
ailure duration was 8.3 years (1.4-18.8 years). Average ejection fraction was 22%
11%-33%), with an average left ventricular end-diastolic dimension of 74 mm
55-94 mm). Previous medical therapy included angiotensin-converting enzyme
nhibitors, -blockers, diuretics, digoxin, and aldosterone receptor blockers. At
mplantation, 17 patients had implantable electronic devices: 1 biventricular pace-
aker, 11 biventricular pacemakers with cardioverter-defibrillators, and 5 implant-
ble cardioverter-defibrillators. Patient comorbidities included hypertension in 10
ases, diabetes mellitus in 8, myocardial infarction in 1, and ventricular tachycardia
n 8. Mean operative time was 68 minutes (42–102 minutes), and implantation time
veraged 15 minutes (5–51 minutes). The average time to ambulation was 1.6 days
1–4 days). The intensive care unit stay averaged 3.3 days (1–16 days), and hospital
tay averaged 6.3 days (4–16 days). Atrial fibrillation occurred in 2 patients, and
here were 2 in-hospital deaths.
onclusions: The Paracor device can be implanted in patients with heart failure and
educed left ventricular function with a high degree of success. Significant surgical
omplications were infrequent. The initial US experience supports the conduct of a
andomized, controlled, pivotal trial.
ptimal medical heart failure therapy consisting of neurohormonal block-
ade with angiotensin-converting enzyme inhibitors and -blockers for
all patients, with biventricular pacing for certain patients with pro-
onged QRS duration, represents the current standard of care for patients with
ymptomatic heart failure. Despite reductions in morbidity and mortality with
edical therapy, there are some patients for whom neurohormonal blockade
vascular Surgery ● January 2007
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ETails to halt the progressive course of this disease.1 In the
urrent era, patients with end-stage heart failure are con-
idered for destination therapy with a left ventricular
ssist device or heart transplantation as a final option.2
ultiple therapies have been used or are under investi-
ation in an attempt to intervene in the progression of this
isease process. These efforts have centered on surgically
eshaping the ventricle or using biventricular pacing to
elieve mechanical and electrical asynchrony.3-10 Re-
ently, other mechanical therapies have been investigated
or the potential to halt the progression of the failing
eart and allow reverse remodeling.11 It has been shown
hat a myocardial constraint device can modify the left
entricular geometry after myocardial infarction in a
heep model.12-14 Myocardial constraint devices have
lso been shown to improve cardiac function, reduce left
entricular volume, and reduce mitral regurgitation in an
vine model of tachycardia-induced progressive dilated
ardiomyopathy.15
The Paracor HeartNet (Paracor Medical, Inc, Sunnyvale,
alif) is an elastic ventricular restraint device that has been
eveloped for patients with heart failure who continue to
ave symptoms and progressive cardiac remodeling, despite
reatment with standard evidence-based therapies. It is im-
lanted around the heart to reduce the wall stress and
otentially allow reverse remodeling. It was hypothesized
hat the HeartNet could be safely implanted through a
inithoracotomy in patients with heart failure and would
ignificantly reduce left ventricular systolic function, lead-
ng to improvement in clinical and functional status. The
afety and efficacy of this device are now under clinical
nvestigation. The initial surgical experience and 6-month
ata for the first 21 patients treated in the United States are
eported here.
ethods
fter investigational review board approval of the Food and Drug
dministration-approved safety and feasibility trial and informed
onsent, 21 patients at five US sites with New York Heart Asso-
iation (NYHA) functional class II or III heart failure who had
een receiving optimal medical therapy for at least 3 months were
elected to undergo implantation of the HeartNet through a
inithoracotomy. Patients with NYHA functional class IV heart
ailure and those with previous cardiac operations were excluded.
atients were evaluated at baseline and at 6-month follow up by
chocardiography, 6-minute walking test, cardiopulmonary exer-
ise testing, NYHA functional class assessment, and the Minne-
Abbreviations and Acronyms
NYHA New York Heart Associationota Living With Heart Failure questionnaire. v
The Journal of Thoracicperative Technique
ll procedures were performed through a left anterior minithora-
otomy with general anesthesia. Patients were positioned supine,
nd fluoroscopy was used to locate the cardiac apex. Minithora-
otomy incision was performed slightly lower than the apex to
llow the correct trajectory for the delivery system. Rib spreading
as performed only to the extent necessary to accommodate the
ntroducer sheath. The pericardium overlying the cardiac apex was
pened and suspended with stay sutures. The introducer was
nserted into the pericardium and expanded (Figure 1, A). An
nobstructed path to the cardiac apex was ensured either by direct
isualization or by passing a 10-mm thoracoscope through the
ntroducer. After confirmation of the introducer positioning, the
elivery system (Figure 1, B) was advanced through the introducer
nder fluoroscopic guidance. The apex was grasped with the
uction cup while the device was inserted and deployed. Once the
elivery system was removed, either direct visualization or the
horacoscope was used synergistically with fluoroscopy to ensure
ppropriate device deployment and location (Figure 2). The peri-
ardium was loosely approximated, and a chest drain was left in
lace. Thoracotomy closure was accomplished in standard fashion.
esults
he HeartNet was successfully implanted in 95% of the
atients enrolled (n  20/21). The baseline demographic
igure 1. A, Introducer sheath used to maintain stable access to
ericardial space. B, HeartNet (Paracor Medical, Inc, Sunnyvale,
alif) delivery system.
igure 2. Paracor HeartNet device (Paracor Medical, Inc, Sunny-
ale, Calif) implanted on a heart model.
and Cardiovascular Surgery ● Volume 133, Number 1 205
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2
ETharacteristics of the patients are listed in Table 1. There
as a preponderance of male patients and those with a
onischemic etiology for heart failure. All patients had been
eceiving optimal medical therapy for a minimum of 3
ABLE 2. Baseline exercise and quality of life parameters
n  21)
arameter
ew York Heart Association functional
class (No.)
II 7/21 (33%)
III 14/21 (66%)
eak ventilation (mL/[kg · min], n  20)
Mean  SD 16.5 3.7
Range 10.8-24
ix-minute walking test (m)
Mean  SD 322 94
Range 168-494
-Natriuretic peptide (pg/mL)
Mean  SD 728 261
Range 23-7575
innesota Living With Heart Failure 60
ABLE 1. Baseline demographic data (n  21)
ge (y)
Mean  SD 52.8  12.4
Range 31.4-72.4
ale (No.) 18 (86%)
hite (No.) 19 (90%)
tiology (No.)
Nonischemic 17 (81%)
Ischemic 4 (19%)
uration of heart failure (y)
Mean  SD 8.3  6.0
Range 1.4-18.8
ardiac medications (No.)
Angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker
21* (100%)
-Blockers 20 (95%)
Diuretics 17 (81%)
Aldosterone receptor blockers 9 (43%)
Digoxin 16 (76%)
edical history and comorbidities (No.)
Hypertension 10 (48%)
Diabetes mellitus 8 (38%)
Myocardial infarction 1 (5%)
Ventricular tachycardia 8 (38%)
Biventricular pacemaker 1 (5%)
Biventricular pacemaker with cardioverter-
defibrillator
11 (52%)
Standard implantable cardioverter-defibrillator 5 (24%)
One patient was receiving both angiotensin-converting enzyme inhibitor
nd angiotensin receptor blocker.questionnaire score
A
06 The Journal of Thoracic and Cardiovascular Surgery ● Januonths. Clinical and functional parameters (Table 2) and
aseline echocardiographic data (Table 3) demonstrated a
oderately ill cohort of patients in NYHA functional
lasses II and III. The patients in functional class II who
ere included (n  7/21) had elevated Minnesota Living
ith Heart Failure scores and dramatically reduced
-minute walking test and cardiopulmonary exercise testing
esults, similar to the patients in functional class III (Table
). Three patients (2 nonischemic etiology, 1 ischemic eti-
logy) demonstrated either 2 or 3 mitral regurgitation
n preoperative transthoracic echocardiography.
rocedural Data
uccessful implantation was accomplished through a left
nterior minithoracotomy in 20 patients. In 1 patient, the
ABLE 3. Baseline echocardiographic parameters (n 21)
arameter
V ejection fraction (%)
Mean  SD 22% 6%
Range 11%-33%
V end-diastolic dimension (mm)
Mean  SD 74 10
Range 55-94
V end-systolic dimension (mm)
Mean  SD 63 11
Range 42-87
iastolic LV volume (cm3)
Mean  SD 370 10
Range 193-619
ystolic LV volume (cm3)
Mean  SD 294 98
Range 141-548
itral regurgitation 2 (No.) 3
iastolic sphericity index*
Mean  SD 0.64  0.12
Range 0.32-0.84)
V, Left ventricular. *Diastolic sphericity index is derived as EDV/ ·
EDL)3/6, where EDV is end-diastolic volume and EDL is end-diastolic
ength.
ABLE 4. Comparison of patients in New York Heart
ssociation functional classes II and III
arameter
Class II
(n  7)
Class III
(n  14)
Combined
(n  21)
innesota Living With Heart
Failure questionnaire score
54 64 60
ix-minute walking test (m) 387 290 322
eak ventilation (mL/[kg · min]) 18.5 15.4 16.5
V ejection fraction (%) 19.5% 22.6% 21.6%
V end-systolic volume (mL) 315 283 294
V end-diastolic volume (mL) 392 360 370
V mass (g, calculated) 337 331 333ll values are mean. LV, Left ventricular.
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ETissues of the pericardium and epicardium were determined
o be extremely friable. After an epicardial laceration ne-
essitated suture control, the procedure was aborted. Among
he 20 patients with successful implantation, the average
otal anesthesia time was 177 minutes (95-402 minutes),
lthough the time from skin incision to skin closure aver-
ged 68 minutes (42–102 minutes; Table 5). The actual time
o deploy the device and the fluoroscopy time constituted
nly a small part of the procedure duration.
ostoperative Course and Adverse Events
he average time to ambulation was 1.6 days (range 1–4
ays, median 1 day). The average intensive care unit stay
as 3.3 days (range 1–16 days, median 1.5 days). Duration
f patient hospitalization averaged 6.3 days (range 4-16
ays, median 5.5 days; Table 5). Perioperative pain man-
gement strategy was selected according to individual sur-
eon preference. Strategies included the use of epidural
atheters, intercostal nerve blocks, local anesthetic infusion
umps placed into the wound, and selected use of ketorolac.
Serious adverse events (Table 6) included 1 case of
nilateral diaphragmatic paresis and pleural effusion, which
esolved completely. The same patient was seen with ane-
ia 1 month after implantation and was found to have
olonic polyps. This same patient returned a third time 3
onths after implantation with a period of obtundation
elated to overmedication with narcotics. Two patients had
trial fibrillation after discharge, which necessitated an ad-
ission in each case for heart failure management and
rrhythmia treatment.
Major adverse events (Table 6) included 2 deaths during
he initial hospitalization and within 30 days of procedure
overall in-hospital and 30-day mortality 10%, n  2/21).
ne patient had significant pulmonary dysfunction and me-
hicillin-resistant Staphylococcus aureus pneumonia neces-
itating reintubation. The patient had progression to multi-
ystem organ failure and died on postoperative day 16. Post
ortem examination confirmed severe bilateral necrotizing
ABLE 5. Index procedural information for 21 patients
range)
Mean Range
nesthesia time (min)* 177 95-402
kin incision to skin closure (min) 68 42-102
ncision length (cm) 9.75 5.5-15
luoroscopy time (min) 6 2-17
mplantation time (min) 15 5-51
ime to ambulation (d) 1.6† 1-4
ntensive care unit stay (d) 3.3† 1-16
ospital stay (d) 6.3† 4-16
Anesthesia time is defined as time from induction of anesthesia to patient
onsciousness. †Median data 1 day, 1.5 days, and 5.5 days, respectively.neumonia with evidence of necrotizing pancreatitis. There s
The Journal of Thoracicas no evidence of device malfunction, nor was the device
mplicated as the cause of death. The pericardial adhesions
o the device were noted to be mild. A second patient also
ad pneumonia necessitating reintubation and a period of
emodynamic instability necessitating vasopressors. This
rogressed to multisystem organ failure, and the patient
ied on postoperative day 14. Autopsy showed evidence of
astrointestinal hemorrhage and bilateral lower lobe consol-
dation of the lungs. The autopsy report did not comment on
ensity of intrapericardial adhesions to the device. These 2
atients had the largest left ventricular end-diastolic dimen-
ions in this series, at 90 and 94 mm, respectively. There
ere no additional major adverse events in the 6-month
ollow up. Overall in-hospital and 30-day mortality was
0% (n  2/21).
Six-month data available (n  10) showed improvement
n multiple clinical and functional parameters (Table 7).
lthough the small number of patients in this sample pre-
ludes reliable statistical analysis, favorable trends were
oted in almost all parameters. The Minnesota Living With
eart Failure scores showed the most dramatic reduction
fter device implantation. Although these data are encour-
ging, they must be interpreted cautiously as uncontrolled
nd unblinded.
iscussion
his is the first report on the US experience with the Paracor
eartNet during the safety and feasibility trial of this myo-
ardial constraint device. Previous reports have detailed the
rchetypal myocardial constraint device, the Acorn CorCap
Acorn Cardiovascular, Inc, St Paul, Minn).11,16 The Para-
or HeartNet differs from the CorCap in several important
ays. The HeartNet is delivered through a minimal access
eft thoracotomy inside the pericardium with the aid of an
ntroducer and delivery system and adheres the heart be-
ause of small textured areas on the epicardial side of the
evice. The HeartNet currently has 12 sizes available and is
ized by echocardiographic parameters, in theory making
he fit consistent across a large size range. It is also con-
ABLE 6. Adverse events
No. of
events
No. of
patients
ulmonary complication 2* 1†
nemia 1 1†
btundation 1 1†
eart failure with hospitalization 2 2‡
trial fibrillation 2 2‡
rocedure-related death 2 2
picardial laceration 1 1
Effusion and diaphragmatic paresis. †Same patient. ‡Same patients.tructed of a nitinol mesh that is both compliant and elastic.
and Cardiovascular Surgery ● Volume 133, Number 1 207
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2
EThe relatively large compliance range reduces the likeli-
ood of development of a constrictive type physiology,
hereas the elasticity may provide some positive epicardial
ressure that may be beneficial relative to the inelastic
onstruction of the CorCap device. The nitinol mesh may
ave an additional benefit of reduced adhesion formation
elative to other materials, although further study is
equired.
Class IV heart failure and adhesions from previous car-
iac operations were considered to be exclusion criteria for
he initial safety and feasibility trial of the Paracor device.
his may have led to a selection bias of a greater number of
atients with nonischemic heart failure. It is unclear at this
ime what the impact of these exclusions would be on the
ventual clinical adaptation of this device. Additionally,
onger follow-up is required to determine the effect of
evice implantation on patients with mitral regurgitation
n  3).
This report demonstrates that the HeartNet can be im-
lanted with a high degree of surgical success (95%) in
atients with heart failure and reduction of left ventricular
unction. The surgical implantation procedure was rela-
ively straightforward, with only a single intraoperative
omplication. Major adverse events occurred in the 2 pa-
ients with the largest hearts, as measured by end-diastolic
imension. This early experience may indicate that, similar
o the CorCap, the patients with the largest end-diastolic
imensions may not be optimal candidates for this therapy.
n the remaining cases the postoperative course parallels
hat might be expected after any thoracotomy in this mod-
rately to severely ill patient cohort. Also similar to general
ostthoracotomy care, adequate preoperative pulmonary
valuation and excellent postoperative pain control appear
o be paramount to success. The 6-month paired data sug-
est a functional and clinical benefit, with a trend toward
everse remodeling, and support the conduct of a random-
ABLE 7. Change from baseline to 6-month paired data (n
arameter (n  10 paired)
ix-minute walking test (m, n  10)
innesota Living With Heart Failure questionnaire score (n  8)
eak ventilation (mL/[kg · min], n  9)
V ejection fraction (%, n  10)
V end-systolic volume (mL, n  10)
V end-diastolic volume (mL, n  10)
V mass (g, calculated; n  8)
V, Left ventricular. *Calculated for Minnesota Living With Heart Failure qu
arameters.zed, controlled, pivotal trial.
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iscussion
r J. Chachques (Paris, France). Number one, I want to ask you
f you evaluated the right ventricular volume dimensions and
unction, because I think you can make more compression in the
ight side than in the left. Number two, what is the evaluation of
he apex in these patients? Do you have some degree of dilatation?
nd finally, do you have some degree of fibrosis in the clinical
xperimental studies which is the ration and material that has made
his device.
Dr. Klodell. Thank you for those questions. Concerning the
ight heart function, we didn’t present that data. The right heart
unction is evaluated by echo. There has not been any significant
hange in right heart function. The right heart pressures were also
onitored perioperatively in the bulk of the patients and implan-
ation of the device did not have any deleterious effects.
As far as the shape of the apex, to which you alluded, many of
hese patients have quite spherical hearts with elevated sphericity
ndices. One of the tricks of deployment is a little bit of apical
raction with that suction cup to try and elongate the apex. thereby
aking the device deploy a little easier.
As to your third question, as far as fibrosis is concerned, we
on’t have any information regarding humans yet, but in the
nimal model at least, the degree of reaction and fibrosis to the
itinol based device has been much less than the other support
evice, and it is hoped that that will translate into humans as well.
Dr S. Gideon (Beer Sheba, Israel). Did you have any bleeding
omplications due to erosion of epicardial blood vessels?
Dr Klodell. No, sir, to date there have been no bleeding
omplications, with the exception of the epicardial laceration from
he introducer that I mentioned. None of the treated patients who
ave had a successful implant have subsequently had any bleeding
omplications.
Dr P. Kurlansky (Miami, Fla). I was wondering if you could
elp us to understand the device a little better. From the graph that
ou showed us, this is an extremely compliant material; therefore,
t doesn’t seem as though there is passive restraint. It would seem
hat in fact this would have a lot of give to it, but it would also be,
s it were, hugging the heart. If you can kind of explain to us a
ittle better the physiology of what is going on or perhaps even the
echanics of what is going on with the device, because it doesn’t
eem to be the same as the other sort of passive restraint device
hat is attempting to be on the market. Thank you. c
The Journal of ThoracicDr Klodell. I think that is a great question: Basically, what are
he differences between this device and the CorCap device? First
f all, this device is implanted completely differently. This is a
inimal access, a 9- to 10-cm thoracotomy incision, and the
ericardium is left intact. This is in contrast to how the other the
evice is implanted via sternotomy. And the sizing of this device,
o which you alluded, is a little different. This device is sized based
n MRI and echo data preoperatively. Currently, there are 12 sizes,
o the device is selected based on the size of the heart you are
oing to put it on. Because nitinol has elasticity that when exposed
o body temperature tends to constrict a little bit, it conforms very
icely to the heart. As opposed to the other device, which is a
assive device that only prevents dilation, this actually has some
lasticity to it; although it is very compliant, it also has elasticity
o it. So there is a constant pressure on the ventricle that is
robably along the order of 4 mm or so of magnitude, and what
hat is going to do long term is unclear at this time. I will share
ith you that the Magdeberg Germany group has submitted an
bstract to the Heart Failure Society in which, hopefully, we will
e hearing then that the elasticity feature may contribute to cardiac
esynchronization.
Dr J. Puskas (Atlanta, Ga). Dr. Klodell, you had 2 out of 10
n this original series die of device related deaths and 1 of 10
borted due to epicardial tear. Tell us about evaluation preopera-
ively for epicardial and pericardial adhesions. How can we avoid
he difficulties inserting these?
Dr Klodell. Very good question. Thank you. Just to be clear, it
as 1 epicardial laceration out of 21 patients and 2 patients out of
he 21 that we presented today.
The preoperative evaluation, the things that we have learned
rom the U.S. patients so far is that patients who have an ischemic
tiology frequently will have some pericardial adhesions. That can
e problematic, certainly. Any patients who have epicardial LV
eads and things like that should be excluded. We didn’t have time
o cover in too much detail the operative approach, but one thing
hat has been very useful is when the introducer is inserted into the
ericardial space to use a thoracoscope through the introducer to
ook at the heart and to try and make sure there are not adhesions
here. When there are adhesions, at least in the European experi-
nce and in our experience in a couple of patients, those adhesions
an be taken down under direct vision using the thoracoscope. But
do think that as far as the one patient that was aborted is
oncerned, preoperative nutrition status and overall qualitative
ssessment of the patient probably would have deterred that im-
lant, and that is something to learn for the future: these need to be
he same kind of relatively healthy patients who you would feel
omfortable putting on bypass for a cardiac operation.
and Cardiovascular Surgery ● Volume 133, Number 1 209
